Home/Xilio Therapeutics/Christopher Haqq
CH

Christopher Haqq

Executive Vice President, Head of Research and Development and Chief Scientific Officer

Xilio Therapeutics

Therapeutic Areas

Xilio Therapeutics Pipeline

DrugIndicationPhase
XTX101Advanced solid tumorsPhase 1
XTX202Advanced solid tumorsPhase 1
XTX301Advanced solid tumorsPreclinical
XTX401Advanced solid tumorsPreclinical